Semaglutide's weight-loss case strengthens as a real-world eye-safety signal draws scrutiny
Read the Sunday Brief →

Study wrapper · #1084

Prescription Sequence Symmetry Analysis of Glucagon-Like Peptide-1 Receptor Agonists and Neuropsychiatric Conditions.

Alfonso Arvez MJ, Wade S, Goordeen D, et al. Clinical pharmacology and therapeutics. 2026.
MixedCohortMentions: Semaglutide

Editor's note

This prescription-sequence analysis reports semaglutide as the dominant agent and finds inverse associations with later antidepressant and substance-use medication starts. The design detects temporal patterns but cannot establish causation or rule out confounding by indication. Regard the inverse associations as signals warranting dedicated study rather than evidence of a therapeutic effect.

Plain-language abstract

Using Australian prescription data, this analysis found that starting a GLP-1 receptor agonist (semaglutide being the most common) was associated with lower subsequent initiation of antidepressants and substance-use-disorder medications. No associations were seen for other neuropsychiatric medication categories.